Drug discovery

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology… Read More

#Business & Investment #News

Neurons in Parkinson's disease
#Biologics / Biotechnology #Collaboration #Drug discovery #Library screening #Neurodegenerative disorders #Partnership #Sironax #X-Chem

Research partners will target neurodegenerative disease

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.   Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute… Read More

#Business & Investment #News

Organoids
#Drug development #Drug discovery #Drug screening #Gene editing #In vitro #In vivo #Organoids #Personalised medicine

Gene editing in organoids: accounting for complexity in drug discovery

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically… Read More

#Exclusive Content

#Clarivate #Drug development #Drug discovery #Market reporting #Personalised medicine #Pharmaceuticals

15 drugs likely to be clinical game-changers

A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented.  Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1… Read More

#Exclusive Content #Trends & Analysis

#Antibodies #Antibody #Antibody discovery workflow #Antibody-based therapeutics #Bethyl Laboratories #Drug discovery

Why choose Bethyl antibodies for your R&D

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

#Acquisition #AmerisourceBergen #Drug discovery #Mergers and acquisitions #Pharma services #PharmaLex

AmerisourceBergen completes acquisition of PharmaLex

AmerisourceBergen Corporation has completed its acquisition of PharmaLex Holding, a provider of tech-enabled services from clinical development consulting to marketing authorisation.  PharmaLex is a global team of scientific, regulatory and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a… Read More

#Business & Investment #News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for… Read More

#Business & Investment #Market Reports #News

#AI / data analytics / healthtech / informatics #Computer modelling #DEL #DNA #Drug discovery #Library screening #Target identification

New trends in DNA-encoded library screening

Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More

#Exclusive Content #Trends & Analysis

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Biomarkers #Data management #Drug discovery #Life sciences #RNA sequencing

The latest drug discovery product launches

Several new products for the life sciences sector have been launched over the last month, from biomarker kits to video-based training platforms. DDW provides an update.  Breath Biopsy VOC Atlas – Owlstone Medical  The Breath Biopsy VOC Atlas is a catalogue of validated and quantitated… Read More

#Editor's Choice #News

#3D cell culture #Drug discovery #Ex Vivo #Genomics #High Content Screening #Life sciences #Molecular Biology #Precision medicine

Podcast: Finding the right cancer drug with high-content screening

This is the latest episode of the free DDW podcast, “Finding the right cancer drug with high-content screening”. It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW. In the article, Lassi Paavolainen, Principal Investigator at the Institute for Molecular… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

AI concept image
#AI #Drug discovery #Novel therapeutics #Pharmaceutical industry #Software

Are claims of the success of AI in drug discovery backed by science? 

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers… Read More

#Business & Investment #Exclusive Content #Opinion